Evidence map›Paper›PMID 31807576›Full record

ReviewAnnals of translational medicine2019

Immunotherapy and targeted therapy-the new roadmap in cancer treatment.

Kamran Shahid, Mustafa Khalife, Raetasha Dabney, Alexandria T Phan

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kamran ShahidDivision of Hematology & Oncology, University of Texas Health Science Center at Tyler, UT Health North Campus Tyler, Tyler, TX, USA.
Mustafa KhalifeDivision of Hematology & Oncology, University of Texas Health Science Center at Tyler, UT Health North Campus Tyler, Tyler, TX, USA.
Raetasha DabneyDivision of Hematology & Oncology, University of Texas Health Science Center at Tyler, UT Health North Campus Tyler, Tyler, TX, USA.
Alexandria T PhanDivision of Hematology & Oncology, University of Texas Health Science Center at Tyler, UT Health North Campus Tyler, Tyler, TX, USA.
The University of Texas Health Science Center at Tyler · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is the new frontier in cancer medicine. This manuscript summarizes historical aspect of immunotherapy, particularly its pathway to drug approval as the main therapeutic modality used in clinical medicine. We will discuss the role of immunotherapy in treating various types of cancers and how the treatment landscape once dominated by chemotherapy is rapidly changing.

Indexed as

cancer treatmentcheck point inhibitorschimeric antigen receptor T-cells (CAR T-cells)Immunotherapy

Identifiers

PMID31807576
PMCPMC6861781
OpenAlexW2906791112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.